Quick Answer: Without insurance in 2026, generic Truvada costs $27 to $70 per month, brand Descovy costs about $2,392 per month, Apretude (cabotegravir) costs $4,229 per bimonthly injection, and the new twice-yearly Yeztugo (lenacapavir) costs $14,109 per dose. Most people never pay these prices: Medicare Part B has covered all FDA-approved PrEP forms at $0 cost-sharing since a September 30, 2024 National Coverage Determination, and Affordable Care Act preventive-services rules require most employer and Marketplace plans to cover Truvada, Descovy, and Apretude, plus required HIV testing and kidney-function labs, at $0 as well. Medicaid covers PrEP in every state, typically for $0 to $4 per prescription. The federal Ready, Set, PrEP program, which once shipped free medication to uninsured patients, stopped enrolling new patients on July 30, 2024 and fully closed on July 18, 2025; uninsured patients today should apply instead to Gilead Advancing Access (Truvada, Descovy, Yeztugo) or the ViiV Healthcare Patient Assistance Program through GSKPAF (Apretude), both of which offer free medication for household income at or below approximately 500% of the federal poverty level.
Truvada, Descovy, Apretude, and Yeztugo are the four FDA-approved medications for HIV pre-exposure prophylaxis, commonly called PrEP, a daily pill or periodic injection that reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Truvada (emtricitabine/tenofovir disoproxil fumarate) was the first PrEP drug approved, in 2012, and has been available as a generic since October 2020. Descovy (emtricitabine/tenofovir alafenamide) followed in October 2019 but is FDA-approved only for people at risk through anal sex, not for people whose only risk is receptive vaginal sex. Apretude (cabotegravir) is a long-acting injectable given every two months, approved in December 2021. Yeztugo (lenacapavir), approved June 18, 2025, is the newest option, an injection given only twice a year.
Federal policy changed the PrEP cost picture dramatically for 2026. CMS issued a final National Coverage Determination on September 30, 2024 that moved all FDA-approved PrEP drugs, oral and injectable, out of Medicare Part D and into Medicare Part A and Part B with zero cost-sharing, including coverage for up to eight HIV tests per year, up to eight counseling sessions per year, and an annual hepatitis B screening. Separately, the Affordable Care Act's preventive-services mandate under Public Health Service Act Section 2713, based on a USPSTF Grade A recommendation, requires most employer-sponsored and Marketplace plans to cover Truvada, Descovy, and Apretude, along with required lab monitoring, without any deductible, copay, or coinsurance. Insurers have been gradually adding Yeztugo to that zero-cost-share list since its 2025 approval; confirm your plan's current formulary before your first fill.
Ready, Set, PrEP was the first nationwide HHS program offering free PrEP medication to uninsured Americans, launched in 2019. The program stopped accepting new enrollments on July 30, 2024 and fully closed on July 18, 2025, a shutdown that coincided with Gilead discontinuing its own free-generic-Truvada program in January 2025. No direct federal replacement exists as of 2026. Uninsured patients now have four main paths to free or low-cost PrEP: the Gilead Advancing Access program for Truvada, Descovy, and Yeztugo; the ViiV Healthcare Patient Assistance Program through GSKPAF for Apretude; state-run PrEP assistance programs currently operating in about a dozen states; and the roughly 15,000 Federally Qualified Health Centers nationwide that offer sliding-fee PrEP regardless of insurance or immigration status. Patients comparing options for weight-loss or diabetes drugs facing similar manufacturer-assistance questions can also review the manufacturer coupon rules on the Ozempic cost page, since the same anti-kickback restrictions apply here.
What HIV PrEP Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same hiv prep can cost many times more at a hospital than at your local pharmacy:
2026 HIV PrEP Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no insurance) | $27 - $14,109 depending on drug | Generic Truvada is cheapest at $27 - $70/month; Yeztugo's twice-yearly dose is the most expensive single charge; see comparison table above |
| ACA-compliant private insurance (employer or Marketplace) | $0 for Truvada, Descovy, and Apretude | Required by the ACA preventive-services mandate (PHS Act Section 2713); labs and clinic visits for PrEP monitoring are also $0. Yeztugo coverage is still being added by some insurers |
| Medicare Part B (2026, PrEP National Coverage Determination) | $0 for all four drugs | Effective Sept 30, 2024, PrEP moved from Part D to Part A/Part B with no deductible, copay, or coinsurance; up to 8 HIV tests and 8 counseling visits per year also covered at $0 |
| Medicaid | $0 - $4/prescription | Every state Medicaid program covers PrEP; expansion-population adults generally pay $0 per ACA rules, while traditional Medicaid may charge a nominal copay in some states |
| Manufacturer patient assistance program (uninsured) | $0 for eligible patients at or below ~500% FPL | Gilead Advancing Access (Truvada, Descovy, Yeztugo) and ViiV's GSKPAF program (Apretude) replaced the discontinued Ready, Set, PrEP program |
Retail prices reflect 2026 GoodRx and manufacturer list-price data. Insurance and Medicare rows reflect the zero-cost-sharing rules in effect for 2026; if you are billed for PrEP under a covered plan, that is very likely a billing error rather than an actual cost obligation.
Source: CMS PrEP National Coverage Determination (2024), CMS Medicare Part D/Part B benefit rules, GoodRx, Gilead Sciences, ViiV Healthcare
Why Hospitals Charge So Much
Hospitals and emergency departments rarely administer routine PrEP, since it is a preventive, self-managed outpatient regimen rather than an acute treatment. When a facility does dispense a bridge supply, for example a patient starting PrEP after a same-day risk assessment in an emergency department, the charge can include a facility fee, a pharmacy dispensing fee, and a physician evaluation charge stacked on top of the drug's acquisition cost. A single Apretude injection given in a hospital-based clinic can be billed at several thousand dollars once facility overhead is added, even though the same dose costs $4,229 or less at a specialty pharmacy and $0 for most insured patients under 2026 coverage rules.
Emergency departments sometimes confuse PrEP with post-exposure prophylaxis (PEP), the 28-day emergency regimen started within 72 hours of a specific exposure. PEP is billed and covered differently than PrEP and typically costs more upfront because it is dispensed as an urgent, short-course treatment rather than a routine preventive prescription. Patients who received a large ED bill after starting HIV prevention medication should ask specifically whether they were billed for PrEP or PEP, since PrEP should be a $0 charge under Medicare Part B or an ACA-compliant plan, while PEP cost-sharing rules can differ by insurer.
HCPCS J-Codes: What Appears on Your Bill
Apretude and Yeztugo are administered in a clinical setting and billed with specific HCPCS Level II J-codes under Medicare Part B. Oral Truvada and Descovy, dispensed at a retail pharmacy, are typically billed by National Drug Code (NDC) rather than a J-code, even though the National Coverage Determination places them under Part B for cost-sharing purposes.
HCPCS J-codes for HIV PrEP| Code | Description | What to look for |
|---|
| J0739 | Injection, cabotegravir, 1mg, for use only as HIV pre-exposure prophylaxis (not for HIV treatment) | Confirm the claim uses J0739 (PrEP-specific) and not J0741 (the cabotegravir/rilpivirine treatment combination), which is billed differently and is not a preventive service |
| J0738 | Injection, lenacapavir, 1mg, for use only as HIV pre-exposure prophylaxis (Yeztugo) | New code effective October 1, 2025; verify your provider's billing system has updated before your first Yeztugo dose to avoid a claim rejection |
| J0752 | Oral lenacapavir lead-in tablets dispensed from clinic stock as part of Yeztugo initiation | Should not generate a separate copay if billed correctly under the Part B PrEP NCD |
All three codes should process at $0 patient cost-sharing under Medicare Part B in 2026. Ask your clinic's billing office to confirm the claim was submitted under the PrEP National Coverage Determination, not a standard drug-administration benefit.
Source: CMS HCPCS Quarterly Update, CMS PrEP National Coverage Determination
Patient Assistance Programs
Gilead Sciences and ViiV Healthcare each run a manufacturer assistance program that replaced much of what Ready, Set, PrEP used to provide before it closed in July 2025. Uninsured patients with modest incomes can often get PrEP free directly from the manufacturer, and commercially-insured patients can use a separate copay card to eliminate any residual cost-sharing their plan does charge.
Patient assistance programs for HIV PrEP| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Gilead Advancing Access | Free Truvada, Descovy, or Yeztugo for uninsured patients at or below approximately 500% FPL ($79,800 for a household of 1 in 2026); no Social Security number or immigration-status documentation required | gileadadvancingaccess.com |
| ViiV Healthcare Patient Assistance Program (via GSKPAF) | Free Apretude for uninsured patients at or below approximately 500% FPL, not enrolled in Medicaid or another government drug plan except Medicare | gskpaf.org/viiv |
| ViiVConnect Copay Program (Apretude, commercially insured) | Reduces out-of-pocket cost to as little as $0 for commercially-insured patients whose plan still charges cost-sharing | viivconnect.com |
| State PrEP Assistance Programs (about 12 states, including CA, NY, IL, MA, WA, VA) | State-funded coverage of medication, labs, and clinical visits for eligible residents regardless of insurance status | nastad.org/prep-access |
| Federally Qualified Health Centers (sliding-fee scale) | Reduced-fee or free PrEP prescribing and monitoring at nearly 15,000 sites nationwide, regardless of insurance or immigration status | findahealthcenter.hrsa.gov |
Manufacturer copay cards and ViiVConnect are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback law (42 U.S.C. Section 1320a-7b). Those patients should rely on the $0 Medicare Part B PrEP benefit or the manufacturer's income-based patient assistance program instead of a commercial copay card.
Source: gileadadvancingaccess.com, gskpaf.org, viivconnect.com, nastad.org, hrsa.gov
Medicare Part D
Medicare stopped covering PrEP under Part D in 2024. CMS's September 30, 2024 National Coverage Determination moved Truvada, Descovy, Apretude, and later Yeztugo out of the Part D prescription drug benefit entirely and into Medicare Part A and Part B as a preventive service, meaning the annual Part D out-of-pocket cap of $2,100 for 2026 simply does not apply to PrEP; there is no deductible, copay, or coinsurance to track because the cost is $0 from the first fill.
Beneficiaries who see a Part D claim or a copay on their Explanation of Benefits for Truvada, Descovy, Apretude, or Yeztugo in 2026 should contact their plan immediately; that claim was very likely processed under the wrong benefit. The Medicare Rights Center and 1-800-MEDICARE can help beneficiaries get an incorrectly billed PrEP claim reprocessed as a $0 Part B preventive service rather than a Part D drug claim. Because PrEP no longer sits on a Part D formulary tier, none of the four drugs has a Medicare Maximum Fair Price under the Inflation Reduction Act of 2022; none was selected for IRA negotiation, and none needed to be, since the $0 preventive-service benefit already makes the negotiated-price mechanism unnecessary for Medicare beneficiaries on PrEP.
Common HIV PrEP Billing Errors
PrEP billing errors are common in 2026 because the 2024 Medicare and ACA coverage changes are still being implemented across pharmacy and clinic systems. Watch for these issues:
- Any Medicare copay, coinsurance, or Part D charge for Truvada, Descovy, Apretude, or Yeztugo in 2026, since all four should process at $0 under the Part B PrEP National Coverage Determination.
- A cost-sharing charge on an ACA-compliant employer or Marketplace plan for Truvada, Descovy, or Apretude, which violates the preventive-services mandate unless the plan is a grandfathered or excepted plan not subject to ACA rules.
- PEP (post-exposure prophylaxis) billed and charged as if it were routine PrEP, or the reverse; the two have different indications and different cost-sharing treatment at some insurers.
- Apretude billed under J0741 (the cabotegravir/rilpivirine HIV-treatment combination code) instead of the correct PrEP-specific code J0739, which can trigger an incorrect denial or cost-sharing charge.
- Manufacturer copay card applied for a Medicare or Medicaid beneficiary, which is prohibited by federal anti-kickback law and can result in a clawback of the claim later.
- Required HIV testing, kidney-function labs, or counseling visits billed separately with a copay when they should be bundled into the $0 PrEP preventive-service benefit.
Frequently Asked Questions
Is there a generic for Truvada, Descovy, or Apretude?
Yes for one of the three. Truvada has had a full generic (emtricitabine/tenofovir DF) since October 2020, costing $27 to $70 per month with a discount coupon. Descovy has no generic sold in the US as of 2026; patent settlements are expected to block generic sales until roughly 2032 to 2036. Apretude and the newer twice-yearly Yeztugo have no generic and no announced US timeline, since both are complex long-acting injectable formulations with their own patents.
How do I apply for a PrEP patient assistance program now that Ready, Set, PrEP has ended?
Apply directly to the drug manufacturer. Gilead Advancing Access covers Truvada, Descovy, and Yeztugo for uninsured patients with household income at or below about 500 percent of the federal poverty level, no Social Security number required. The ViiV Healthcare Patient Assistance Program through GSKPAF covers Apretude at the same roughly 500 percent FPL threshold. Both require proof of income, proof of US residency, and a valid prescription, and typically process applications within 5 to 10 business days.
Can I use a PrEP manufacturer savings card with Medicare?
No. Federal anti-kickback law bars manufacturer copay cards, including ViiVConnect, from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries. This restriction matters less for PrEP than for most drugs, however, because Medicare Part B has covered Truvada, Descovy, Apretude, and Yeztugo at $0 cost-sharing since a September 30, 2024 National Coverage Determination, so most Medicare beneficiaries do not need a savings card at all.
What if my insurance denies coverage or bills me for PrEP?
Request a written denial notice or explanation of benefits, then file a formal appeal citing the ACA preventive-services mandate (Public Health Service Act Section 2713) for private plans or the 2024 Medicare National Coverage Determination for Part B claims. Most PrEP denials or copay charges in 2026 are processing errors rather than valid coverage decisions. If the appeal is not resolved quickly, apply for the manufacturer PAP as a temporary fallback.
Does Medicare cover PrEP for free in 2026?
Yes. Since a September 30, 2024 National Coverage Determination, Medicare Part B covers all four FDA-approved PrEP drugs, oral Truvada and Descovy and the injectables Apretude and Yeztugo, with no deductible, copay, or coinsurance. Medicare also covers up to eight HIV tests per year, up to eight counseling sessions per year, and an annual hepatitis B screening at $0 as part of the same preventive-service benefit. The general 2026 Medicare Part D annual out-of-pocket cap of $2,100 does not apply to PrEP since it is billed under Part B, not Part D.
What does PrEP cost without insurance at the pharmacy counter in 2026?
Generic Truvada costs $27 to $70 per month with a GoodRx coupon, the cheapest of the four options. Brand Descovy costs about $2,392 per month. Apretude costs $4,229 per bimonthly injection, roughly $2,115 per month on an equivalent basis. The newest option, Yeztugo, costs $14,109 per twice-yearly dose, about $28,218 per year. Uninsured patients at these cash prices should apply for Gilead Advancing Access or the ViiV Healthcare PAP instead of paying out of pocket.
Do I qualify for a PrEP patient assistance program based on my income?
Both major PrEP manufacturer programs use roughly the same threshold: approximately 500 percent of the federal poverty level, which is $79,800 for a household of one in 2026 and $165,000 for a household of four. You must also be uninsured or have coverage that does not include the specific PrEP drug you need, and you must have a valid US prescription. Gilead Advancing Access does not require a Social Security number, making it accessible to undocumented residents.
What is the difference between Truvada, Descovy, Apretude, and Yeztugo?
Truvada is a once-daily generic tablet approved for anyone at risk of sexually acquired or injection-drug-use HIV. Descovy is a once-daily brand tablet approved only for people at risk through anal sex, not for people whose only risk is receptive vaginal sex. Apretude is an injection given every two months, approved for adults and adolescents regardless of sex. Yeztugo, approved in June 2025, is an injection given only twice a year, the longest-acting PrEP option available as of 2026.
Does the IRA negotiated Medicare price apply to Truvada, Descovy, or Apretude?
No. None of the four PrEP drugs was selected for Inflation Reduction Act price negotiation, so none carries a Medicare Maximum Fair Price, and none needed to be selected, since PrEP moved off the Part D formulary tier entirely in September 2024 and became a $0 cost-sharing Part B preventive service. The Inflation Reduction Act's negotiated-price mechanism exists to lower Part D drug costs; PrEP already costs Medicare beneficiaries $0, so the negotiation process simply does not apply here.
